Skip to content

Released Apr 30, 2021, during market hours

10-Q filed Apr 30, 2021, 30 days after period end · 0001564590-21-022412

Q1 2021 · 10-Q
Revenue—
Net Income-$7.42MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.14N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$7,339,000N/M
Operating Cash Flow-$5,605,000N/M
Free Cash Flowderived-$5,733,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ1 2021Q1 2020Q1 2019
Net Income-$7.42M-$6.40M-$10.77M
EPS Diluted-$0.14-$0.90—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR